Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 10, 2005

View Archived Issues

Takeda licenses Omacor for Japanese market

Theravance and Astellas collaborate on telavancin

Compassionate access program for Sativex in Spain

New phase I combination study of Anyara and Taxotere in NSCLC

European orphan drug designation for alfimeprase for acute PAO

Targeting Hsp90: a new therapeutic avenue for SBMA

Savvy phase III HIV prevention trial in Ghana to be discontinued

Phase II study of DP-b99 in acute stroke patients recommended to continue

KRP-103: A new NK1 antagonist for urinary incontinence

Astellas selects targets for diabetes and obesity in Metabolex collaboration

Vical receives milestone payment on initiation of DNA cancer vaccine trial

BioAdvance leads seed funding for NuPathe

FDA clearance for phase I/II study of SPC-2996 in CLL

Series B financing to advance Portola's cardiovascular portfolio

Celsion supports ThermoDox study at Duke University

Argos' RNA-loaded dendritic cell vaccine to be studied for CLL

Axonyx updates pipeline status

Novartis signs agreement for glaucoma treatment Y-39983

FDA approval for new Kaletra tablets formulation

Roche announces MAb therapy for critical limb ischemia and peripheral arterial occlusive disease

Recent Jerini patent describes novel therapeutic agents for eye, skin and joint disorders

Novel agents for diabetes reported in recent patent literature

Eisai presents six-month recap

Gardasil vaccine reported to prevent the development of HPV-related cervical lesions

Temsirolimus found safe and effective in endometrial cancer

Improved survival achieved with sorafenib in patients with advanced renal cell carcinoma

Update on the effects and safety of sunitinib in GIST

Phosphate binders show promise in the treatment of pseudoxanthoma elasticum

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...